Pfizer, Valneva say 'positive' result for Lyme disease vaccine candidate booster

Pfizer says it intends to submit regulatory applications for VLA15, which Valneva presents as being "the most advanced Lyme disease vaccine candidate currently in clinical development", to both the European Medicines Agency and U.S. Food and Drug Administration by 2026 if the phase 3 clinical trial, launched last year, gives positive results.